ArticleFrontiers in public health2026
Prevalence and genotype distribution of human papillomavirus among 15,224 gynecological outpatients in Xuzhou, China, during 2023-2025.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated HPV prevalence and genotype distribution among gynecological outpatients at the Affiliated Hospital of Xuzhou Medical University, aiming to inform region-specific cervical cancer prevention strategies. Methods: We determined the HPV subtypes by polymerase chain reaction (PCR) and analyzed the HPV prevalence, genotype distribution in 15,224 gynecological outpatients by age group and year. Results: Among the 15,224 outpatients, 4,884 (32.08%) tested positive for HPV, with single high-risk HPV (HR-HPV) infection being the predominant pattern (16.48%). The top five HR-HPV genotypes were HPV52 (5.58%), 16 (4.93%), 58 (4.49%), 53 (3.54%), and 56 (2.51%). The top three low-risk HPV (LR-HPV) genotypes were HPV42 (3.30%), 81 (2.16%), and 43 (1.76%). From 2023 to 2025, the overall HPV prevalence among this study population exhibited a significant increasing trend, rising from 27.57 to 36.63% ( Conclusion: The prevalence of HPV infection among women attending gynecological outpatient clinics of the Affiliated Hospital of Xuzhou Medical University is relatively high and has demonstrated an increasing trend over the study period. Adolescents and middle-aged and older women exhibit higher HPV prevalence. The predominant genotypes are HR-HPV52, 16, 58, 53, and 56, as well as LR-HPV42, 81, and 43. In addition to strengthening universal health education, the observed age-specific distribution suggests that young women and middle-aged and older women may be important target groups for future prevention strategies. Furthermore, the high prevalence of non-vaccine-covered genotypes (HPV53, 56, 42, 81, and 43) warrants continued surveillance and further investigation of their clinical significance, although these implications should be considered preliminary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.